{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:53:44Z","timestamp":1791298424048,"version":"4.1.0"},"reference-count":75,"publisher":"Oxford University Press (OUP)","issue":"S1","license":[{"start":{"date-parts":[[2009,9,1]],"date-time":"2009-09-01T00:00:00Z","timestamp":1251763200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>In treating moderate to severe anemia of chronic kidney disease (CKD), oral iron is effective only in a minority of nondialysis patients. Intravenous iron is more effective and can raise levels of hemoglobin even without the use of erythropoiesis-stimulating agents (ESAs). Unfortunately, the current assays of iron status that are presently widely available are not especially helpful in predicting response. In patients on dialysis, i.v. iron is effective over a wide range of serum ferritin from &amp;lt;100 ng\/ml to 800 ng\/ml. None of the three available randomized controlled trials comparing oral with i.v. iron showed evidence of nephrotoxicity caused by i.v. iron.<\/jats:p>\n               <jats:p>Iron deficiency is a risk factor for thrombocytosis and should, wherever possible, be avoided. Optimal coadministration of iron may reduce the risk for ESA-driven cardiovascular events. Increased total body iron stores (imperfectly reflected by serum ferritin levels in CKD) do not appear to be related to such events or hospitalization in CKD; it is unclear what other risk factors and mechanisms need to be considered.<\/jats:p>\n               <jats:p>In the appreciable proportion of patients with both renal and cardiac dysfunction, management is further complicated by a vicious circle (which can be characterized as cardiorenal anemia syndrome) in which CKD, heart failure, and anemia exacerbate each other. In such patients, correction of anemia appears to improve cardiac function and quality of life without a greater risk for adverse events.<\/jats:p>","DOI":"10.1634\/theoncologist.2009-s1-22","type":"journal-article","created":{"date-parts":[[2009,9,17]],"date-time":"2009-09-17T17:49:20Z","timestamp":1253209760000},"page":"22-33","source":"Crossref","is-referenced-by-count":59,"title":["Iron Metabolism, Iron Deficiency, Thrombocytosis, and the Cardiorenal Anemia Syndrome"],"prefix":"10.1093","volume":"14","author":[{"given":"Anatole","family":"Besarab","sequence":"first","affiliation":[{"name":"Wayne State University, Detroit, Michigan, USA"},{"name":"Henry Ford Hospital, Detroit, Michigan, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter Hermann","family":"H\u00f6rl","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald","family":"Silverberg","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Tel Aviv Medical Center, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2009,9,1]]},"reference":[{"key":"2021122207231569900_R1","first-page":"825","article-title":"Within-subject biological variation of hematological quantities and analytical goals","volume":"116","author":"Dot","year":"1992","journal-title":"Arch Pathol Lab Med"},{"key":"2021122207231569900_R2","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1053\/ajkd.2003.50030","article-title":"Effect of variability in anemia management on hemoglobin outcomes in ESRD","volume":"41","author":"Lacson","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"2021122207231569900_R3","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.2215\/CJN.01110306","article-title":"Hemoglobin level variability: Associations with comorbidity, intercurrent events, and hospitalizations","volume":"1","author":"Ebben","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"2021122207231569900_R4","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2215\/CJN.01610407","article-title":"Hemoglobin level variability: Associations with mortality","volume":"3","author":"Gilbertson","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"2021122207231569900_R5","doi-asserted-by":"crossref","first-page":"777","DOI":"10.2215\/CJN.04281007","article-title":"History-adjusted marginal structural analysis of the association between hemoglobin variability and mortality among chronic hemodialysis patients","volume":"3","author":"Brunelli","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"2021122207231569900_R6","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1053\/j.ajkd.2007.06.008","article-title":"KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for chronic kidney disease: 2007 update of hemoglobin target","volume":"50","author":"National Kidney Foundation Kidney Disease Outcomes Quality Initiative","year":"2007","journal-title":"Am J Kidney Dis"},{"key":"2021122207231569900_R7","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/ki.2008.295","article-title":"Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes","volume":"74","author":"Szczech","year":"2008","journal-title":"Kidney Int"},{"key":"2021122207231569900_R8","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/S0140-6736(07)60165-2","article-title":"Haemoglobin targets: We were wrong, time to move on","volume":"369","author":"Strippoli","year":"2007","journal-title":"Lancet"},{"key":"2021122207231569900_R9","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1056\/NEJMoa065485","article-title":"Correction of anemia with epoetin alfa in chronic kidney disease","volume":"355","author":"Singh","year":"2006","journal-title":"N Engl J Med"},{"key":"2021122207231569900_R10","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJM199808273390903","article-title":"The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin","volume":"339","author":"Besarab","year":"1998","journal-title":"N Engl J Med"},{"key":"2021122207231569900_R11","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa062276","article-title":"Normalization of hemoglobin level in patients with chronic kidney disease and anemia","volume":"355","author":"Drueke","year":"2006","journal-title":"N Engl J Med"},{"key":"2021122207231569900_R12","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.2215\/CJN.04601007","article-title":"Greater epoetin alfa responsiveness is associated with improved survival in hemodialysis patients","volume":"3","author":"Kilpatrick","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"2021122207231569900_R13","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1053\/ajkd.2002.31999","article-title":"United States Renal Data System assessment of the impact of the National Kidney Foundation-Dialysis Outcomes Quality Initiative guidelines","volume":"39","author":"Collins","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"2021122207231569900_R14","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1046\/j.1523-1755.2003.00937.x","article-title":"The effects of higher hemoglobin levels on mortality and hospitalization in hemodialysis patients","volume":"63","author":"Ofsthun","year":"2003","journal-title":"Kidney Int"},{"key":"2021122207231569900_R15","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1053\/j.ajkd.2008.05.029","article-title":"Erythropoietin, iron depletion, and relative thrombocytosis: A possible explanation for hemoglobin-survival paradox in hemodialysis","volume":"52","author":"Streja","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"2021122207231569900_R16","article-title":"US Renal Data System Annual Data Report","volume-title":"Atlas of End-Stage Renal Disease in the United States [2007]","author":"U.S. Renal Data System"},{"key":"2021122207231569900_R17","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1681\/ASN.V12112465","article-title":"Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36 to 39%","volume":"12","author":"Collins","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"2021122207231569900_R18","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1681\/ASN.2005090997","article-title":"Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients","volume":"17","author":"Regidor","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"2021122207231569900_R19","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/S0272-6386(04)01086-8","article-title":"Epoetin requirements predict mortality in hemodialysis patients","volume":"44","author":"Zhang","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"2021122207231569900_R20","volume-title":"FDA Advisory Committee Briefing Document","author":"U.S. Food and Drug Administration"},{"key":"2021122207231569900_R21","first-page":"2","volume-title":"Red Cell Manual","author":"Hillman","year":"1997","edition":"Seventh Edition"},{"key":"2021122207231569900_R22","first-page":"126","volume-title":"Biology of erythropoiesis, erythroid differentiation, and maturation","author":"Papayannopoulou","year":"2005","edition":"Fourth Edition"},{"key":"2021122207231569900_R23","volume-title":"Brock","year":"1994","edition":"First Edition"},{"key":"2021122207231569900_R24","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1056\/NEJM199912233412607","article-title":"Disorders of iron metabolism","volume":"341","author":"Andrews","year":"1999","journal-title":"N Engl J Med"},{"key":"2021122207231569900_R25","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1182\/blood-2004-08-3375","article-title":"Hepcidin excess induces the sequestration of iron and exacerbates tumor-associated anemia","volume":"105","author":"Rivera","year":"2005","journal-title":"Blood"},{"key":"2021122207231569900_R26","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/ki.1997.323","article-title":"Reticulocyte hemoglobin content in the evaluation of iron status of hemodialysis patients","volume":"52","author":"Fishbane","year":"1997","journal-title":"Kidney Int"},{"key":"2021122207231569900_R27","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1097\/01.ASN.0000034200.82278.DC","article-title":"Iron status and hemoglobin level in chronic renal insufficiency","volume":"13","author":"Hsu","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"2021122207231569900_R28","first-page":"161","article-title":"Iron deficiency is a common cause of anemia in chronic kidney disease and can often be corrected with intravenous iron","volume":"19","author":"Gotloib","year":"2006","journal-title":"J Nephrol"},{"key":"2021122207231569900_R29","first-page":"170","article-title":"Comparison of oral versus intravenous iron therapy in predialysis patients of chronic renal failure receiving recombinant human erythropoietin","volume":"51","author":"Aggarwal","year":"2003","journal-title":"J Assoc Physicians India"},{"key":"2021122207231569900_R30","doi-asserted-by":"crossref","first-page":"c55","DOI":"10.1159\/000085049","article-title":"Venofer Clinical Studies Group. Comparison of intravenous iron sucrose to oral iron in the treatment of anemic patients with chronic kidney disease not on dialysis","volume":"100","author":"Charytan","year":"2005","journal-title":"Nephron Clin Pract"},{"key":"2021122207231569900_R31","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1093\/ndt\/16.5.967","article-title":"A randomized study of oral vs intravenous iron supplementation in patients with progressive renal insufficiency treated with erythropoietin","volume":"16","author":"Stoves","year":"2001","journal-title":"Nephrol Dial Transplant"},{"key":"2021122207231569900_R32","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1111\/j.1523-1755.2005.00758.x","article-title":"A randomized controlled trial comparing IV iron sucrose to oral iron in anemic patients with nondialysis-dependent CKD","volume":"68","author":"Van Wyck","year":"2005","journal-title":"Kidney Int"},{"key":"2021122207231569900_R33","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1681\/ASN.2007101156","article-title":"Ferumoxytol for treating iron deficiency anemia in CKD","volume":"19","author":"Spinowitz","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"2021122207231569900_R34","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1681\/ASN.2006091034","article-title":"DRIVE Study Group. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: Results of the Dialysis Patients\u2019 Response to IV Iron with Elevated Ferritin (DRIVE) study","volume":"18","author":"Coyne","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"2021122207231569900_R35","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1681\/ASN.2007050606","article-title":"Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritin","volume":"19","author":"Kapoian","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"2021122207231569900_R36","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1038\/sj.ki.5002223","article-title":"DRIVE Study Group. Predictors of the response to treatment in anemic hemodialysis patients with high serum ferritin and low transferrin saturation","volume":"71","author":"Singh","year":"2007","journal-title":"Kidney Int"},{"issue":"suppl 1","key":"2021122207231569900_R37","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.2215\/CJN.01490506","article-title":"Assessing iron status: Beyond serum ferritin and transferrin saturation","volume":"1","author":"Wish","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"2021122207231569900_R38","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.2169\/internalmedicine.44.1025","article-title":"Thrombocytosis in iron deficiency anemia","volume":"44","author":"Dan","year":"2005","journal-title":"Intern Med"},{"key":"2021122207231569900_R39","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.2169\/internalmedicine.44.1090","article-title":"Iron deficiency anemia with marked thrombocytosis complicated by central retinal vein occlusion","volume":"44","author":"Nagai","year":"2005","journal-title":"Intern Med"},{"key":"2021122207231569900_R40","doi-asserted-by":"crossref","first-page":"589","DOI":"10.2176\/nmc.46.589","article-title":"Cerebral venous sinus thrombosis associated with iron deficiency: Two case reports","volume":"46","author":"Kinoshita","year":"2006","journal-title":"Neurol Med Chir (Tokyo)"},{"key":"2021122207231569900_R41","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S0887-8994(96)00290-1","article-title":"Iron deficiency: A cause of stroke in infants and children","volume":"16","author":"Hartfield","year":"1997","journal-title":"Pediatr Neurol"},{"key":"2021122207231569900_R42","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s00415-006-0411-9","article-title":"Anemia as a risk factor for cerebral venous thrombosis? An old hypothesis revisited. Results of a prospective study","volume":"254","author":"Stolz","year":"2007","journal-title":"J Neurol"},{"key":"2021122207231569900_R43","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s00277-007-0416-1","article-title":"Iron and thrombosis","volume":"87","author":"Franchini","year":"2008","journal-title":"Ann Hematol"},{"key":"2021122207231569900_R44","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1097\/00043426-200308000-00023","article-title":"Amino acid sequence homology of thrombopoietin and erythropoietin may explain thrombocytosis in children with iron deficiency anemia","volume":"25","author":"Bilic","year":"2003","journal-title":"J Pediatr Hematol Oncol"},{"key":"2021122207231569900_R45","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1525-139X.2008.00435.x","article-title":"Thrombosis with erythropoietic stimulating agents\u2014does iron-deficient erythropoiesis play a role?","volume":"21","author":"Dahl","year":"2008","journal-title":"Semin Dial"},{"issue":"suppl 1","key":"2021122207231569900_R46","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.2215\/CJN.01390406","article-title":"The fascinating but deceptive ferritin: To measure it or not to measure it in chronic kidney disease?","volume":"1","author":"Kalantar-Zadeh","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"issue":"suppl 1","key":"2021122207231569900_R47","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1634\/theoncologist.2009-S1-43","article-title":"Anemia management in oncology and hematology","volume":"14","author":"Spivak","year":"2009","journal-title":"The Oncologist"},{"key":"2021122207231569900_R48","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S0140-6736(81)92463-6","article-title":"Iron and the sex difference in heart disease risk","volume":"1","author":"Sullivan","year":"1981","journal-title":"Lancet"},{"key":"2021122207231569900_R49","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1161\/01.CIR.0000066910.02844.D0","article-title":"Chronic iron administration increases vascular oxidative stress and accelerates arterial thrombosis","volume":"107","author":"Day","year":"2003","journal-title":"Circulation"},{"key":"2021122207231569900_R50","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.jacc.2008.04.061","article-title":"Anemia and mortality in heart failure patients: a systematic review and meta-analysis","volume":"52","author":"Groenveld","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"2021122207231569900_R51","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.amjmed.2008.03.039","article-title":"Anemia and heart failure: A community study","volume":"121","author":"Dunlay","year":"2008","journal-title":"Am J Med"},{"key":"2021122207231569900_R52","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1161\/CIRCULATIONAHA.105.577577","article-title":"Hemoglobin level, chronic kidney disease, and the risks of death and hospitalization in adults with chronic heart failure: The Anemia in Chronic Heart Failure: Outcomes and Resource Utilization (ANCHOR) study","volume":"113","author":"Go","year":"2006","journal-title":"Circulation"},{"key":"2021122207231569900_R53","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0735-1097(01)01470-X","article-title":"Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction","volume":"38","author":"Al-Ahmad","year":"2001","journal-title":"J Am Coll Cardiol"},{"key":"2021122207231569900_R54","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1681\/ASN.2005030270","article-title":"Kidney function and mortality among patients with left ventricular systolic dysfunction","volume":"17","author":"Khan","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"2021122207231569900_R55","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/j.amjcard.2006.11.055","article-title":"Anemia as a risk factor for kidney function decline in individuals with heart failure","volume":"99","author":"Bansal","year":"2007","journal-title":"Am J Cardiol"},{"key":"2021122207231569900_R56","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1136\/hrt.70.4.357","article-title":"Pathogenesis of oedema in chronic severe anemia: Studies of body water and sodium, renal function, haemodynamic variables, and plasma hormones","volume":"70","author":"Anand","year":"1993","journal-title":"Br Heart J"},{"key":"2021122207231569900_R57","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1161\/01.CIR.80.2.299","article-title":"Edema of cardiac origin. Studies of body water and sodium, renal function, hemodynamic indices, and plasma hormones in untreated congestive cardiac failure","volume":"80","author":"Anand","year":"1989","journal-title":"Circulation"},{"key":"2021122207231569900_R58","first-page":"265","article-title":"Cardiovascular adaptation to chronic anemia in the elderly: An echocardiographic study","volume":"27","author":"Aessopos","year":"2004","journal-title":"Clin Invest Med"},{"key":"2021122207231569900_R59","doi-asserted-by":"crossref","first-page":"527","DOI":"10.2143\/AC.59.5.2005228","article-title":"Haemoglobin level influences brain natriuretic peptide concentration","volume":"59","author":"Tsuji","year":"2004","journal-title":"Acta Cardiol"},{"key":"2021122207231569900_R60","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.cardfail.2006.02.007","article-title":"Secular trends in renal dysfunction and outcomes in hospitalized heart failure patients","volume":"12","author":"Owan","year":"2006","journal-title":"J Card Fail"},{"key":"2021122207231569900_R61","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.jacc.2004.10.038","article-title":"Angiotensin-converting enzyme inhibitor as a risk factor for the development of anemia, and the impact of incident anemia on mortality in patients with left ventricular dysfunction","volume":"45","author":"Ishani","year":"2005","journal-title":"J Am Coll Cardiol"},{"issue":"suppl 1","key":"2021122207231569900_R62","first-page":"S93","article-title":"The cardio renal anemia syndrome: Correcting anemia in patients with resistant congestive heart failure can improve both cardiac and renal function and reduce hospitalizations","volume":"60","author":"Silverberg","year":"2003","journal-title":"Clin Nephrol"},{"key":"2021122207231569900_R63","doi-asserted-by":"crossref","first-page":"4359","DOI":"10.1210\/jc.2004-0678","article-title":"Anemia in patients with type 1 diabetes","volume":"89","author":"Thomas","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"2021122207231569900_R64","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.2337\/diacare.28.5.1118","article-title":"Anemia and diabetes in the absence of nephropathy","volume":"28","author":"Craig","year":"2005","journal-title":"Diabetes Care"},{"key":"2021122207231569900_R65","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.ejheart.2008.06.015","article-title":"The role of correction of anaemia in patients with congestive heart failure: A short review","volume":"10","author":"Silverberg","year":"2008","journal-title":"Eur J Heart Fail"},{"key":"2021122207231569900_R66","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.ahj.2007.07.034","article-title":"Improvement of anemia with erythropoietin and intravenous iron reduces sleep-related breathing disorders and improves daytime sleepiness in anemic patients with congestive heart failure","volume":"154","author":"Zilberman","year":"2007","journal-title":"Am Heart J"},{"key":"2021122207231569900_R67","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1161\/CIRCULATIONAHA.107.698514","article-title":"Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia","volume":"117","author":"Ghali","year":"2008","journal-title":"Circulation"},{"key":"2021122207231569900_R68","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1093\/eurheartj\/ehm328","article-title":"Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia","volume":"28","author":"Van Veldhuisen","year":"2007","journal-title":"Eur Heart J"},{"key":"2021122207231569900_R69","doi-asserted-by":"crossref","DOI":"10.1136\/hrt.2008.161091","article-title":"Erythropoietin treatment in patients with chronic heart failure: A meta-analysis","author":"Van der Meer","year":"2009","journal-title":"Heart"},{"key":"2021122207231569900_R70","volume-title":"Interim Report on Reduction of Events With Darbepoetin Alfa in Heart Failure (RED HF Study)","year":"2008"},{"key":"2021122207231569900_R71","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s10741-008-9087-9","article-title":"Anemia treatment in chronic kidney disease: Shifting uncertainty","volume":"13","author":"Pfeffer","year":"2008","journal-title":"Heart Fail Rev"},{"key":"2021122207231569900_R72","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.jacc.2005.03.044","article-title":"Erythropoietin induces neovascularization and improves cardiac function in rats with heart failure after myocardial infarction","volume":"46","author":"van der Meer","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"2021122207231569900_R73","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/j.jacc.2006.07.015","article-title":"Intravenous iron alone for the treatment of anemia in patients with chronic heart failure","volume":"48","author":"Bolger","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"2021122207231569900_R74","first-page":"236","article-title":"Intravenous iron without erythropoietin for the treatment of iron deficiency anemia in patients with moderate to severe congestive heart failure and chronic renal insufficiency","volume":"21","author":"Usmanov","year":"2008","journal-title":"J Nephrol"},{"key":"2021122207231569900_R75","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1016\/j.jacc.2007.07.029","article-title":"Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency","volume":"50","author":"Toblli","year":"2007","journal-title":"J Am Coll Cardiol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2009-S1-22","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2009-S1-22","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/14\/S1\/22\/41841453\/oncolo_14_s1_22.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/14\/S1\/22\/41841453\/oncolo_14_s1_22.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,22]],"date-time":"2021-12-22T07:53:41Z","timestamp":1640159621000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/14\/S1\/22\/6398908"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9,1]]},"references-count":75,"journal-issue":{"issue":"S1","published-online":{"date-parts":[[2009,9,1]]},"published-print":{"date-parts":[[2009,9,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2009-s1-22","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2009,9,1]]},"published":{"date-parts":[[2009,9,1]]}}}